antibodies

According to modeling from the CDC, a pair of Omicron subvariants (BQ.1 & BQ.1.1) now account for half of all SARS.CoV.2 infections in the US. New research also indicates current monoclonal antibody treatments may be ineffective against BQ variants.

In the first big real-world test for monoclonal antibodies against malaria a new study has reported extraordinarily promising results, with a novel therapy found to be 88.2% effective at preventing infections across a six-month period.

A new study has provided more evidence gut bacteria plays a role in the development of rheumatoid arthritis. The research suggests an abnormal immune response to a common species of gut bacteria could influence the development of the disease.

The first successful results from a trial testing a drug designed to slow symptoms of Alzheimer’s have been revealed, but experts suggest more data is needed to understand exactly how meaningful this treatment will be for patients in the real world.

Positive Phase 3 trial results for a new antibody treatment targeting rheumatoid arthritis have recently been reported. The therapy is hoped to offer a new option to patients struggling with current treatments and should be available within the next year.

A study has homed in on a part of the SARS-CoV-2 spike protein that is shared across all variants. The research reveals an antibody fragment that can block the virus from entering human cells, paving the way for therapies to neutralize all variants.

An innovative new rapid test promises to give people the ability to easily measure their COVID-19 immunity. The test tracks levels of neutralizing antibodies in a drop of blood, helping a person evaluate their susceptibility to SARS-CoV-2 infection.

Promising results from a Phase 1 human trial testing a novel monoclonal antibody treatment designed to prevent malaria infection reveal almost every volunteer resisted infection after being deliberately exposed to malaria.

Clumps of misfolded proteins that gather in the brain have been linked to neurodegenerative diseases like Parkinson’s. Now, newly identified nanobodies show promise in destabilizing the structure of these clumps, potentially leading to new treatments.

New research has found a long bout of moderate exercise following COVID-19 or influenza vaccination can amplify the body’s immune response. The study showed 90 minutes of exercise immediately after vaccination increased antibody responses weeks later.

The FDA has issued an emergency use authorization for bebtelovimab, a monoclonal antibody designed to reduce risk of hospitalization and death from COVID-19. This comes after previous antibody treatments were found to be ineffective against Omicron.

Researchers in Japan have demonstrated a new antibody treatment for prostate cancer. The drug helps reverse a nasty trick that cancer cells play on the immune system, with promising results shown in experiments in dogs with the cancer.